<DOC>
	<DOCNO>NCT01353209</DOCNO>
	<brief_summary>The hypothesis study estrogen suppression aromatase inhibitor postmenopausal woman Lymphangioleiomyomatosis ( LAM ) prevent delay progression lung disease result decrease rate decline FEV1</brief_summary>
	<brief_title>Trial Aromatase Inhibition Lymphangioleiomyomatosis</brief_title>
	<detailed_description>Lymphangioleiomyomatosis , LAM , uncommon , progressive , cystic lung disease predominantly affect young woman . Pulmonary parenchymal change consistent LAM find one third woman tuberous sclerosis complex ( TSC ) , autosomal dominant tumor suppressor syndrome . LAM also occur sporadic form associate germ line mutation TSC gene . Recent evidence recurrent LAM lung transplantation result seed graft remote source suggest metastatic mechanism disease . Since LAM occur almost exclusively woman , exposure estrogen either exogenously pregnancy exacerbate LAM , estrogen suppression might expect prevent delay progression disease . In preclinical study , estrogen induces growth TSC2-deficient cell tumor cell derive LAM patient . In xenograft model lymphangioleiomyomatosis present Dr. Yu 2008 LAM Research Meeting , estrogen promote pulmonary metastasis tuberin-deficient ELT3 cell ( TSC2-deficient rat uterine leiomyoma cell ) female ovariectomized CB-17-scid mouse , estrogen inhibitor fulvestrant completely block estrogen-promoted pulmonary metastasis . This work recently publish . Letrozole nonsteroidal aromatase inhibitor ( inhibitor estrogen synthesis ) ( 14 ) . It chemically describe 4,4'- ( 1H-1,2,4-Triazol-1-ylmethylene ) diben-zonitrile . In postmenopausal woman , estrogens mainly derive action aromatase enzyme , convert adrenal androgen ( primarily androstenedione testosterone ) estrone estradiol . The suppression estrogen biosynthesis peripheral tissue cancer tissue therefore achieve specifically inhibit aromatase enzyme .</detailed_description>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>All patient least must diagnosis pulmonary lymphangioleiomyomatosis define one following : CT chest compatible LAM biopsy cytology consistent withLAM . CT chest consistent LAM set tuberous sclerosis , renal angiomyolipomata , cystic abdominal lymphangioma , chylous effusion chest abdomen , serum VEGFD &gt; 800 pg/uL . All patient must post bronchodilator FEV1 ≤80 % predict DLCO ≤70 % predict RV≥120 % predict All patient must postmenopausal female define one following : Prior bilateral oophorectomy bilateral ovarian irradiation . If age great 55 year , menstrual period 12 month longer . If age 55 year young , must estradiol level postmenopausal range absence current use progestational agent . If still premenopausal , may enter render medically postmenopausal clinical ground use gonadotropin release hormone ( e.g . leuprolide ) , long serum estradiol , FSH , LH postmenopausal range Patients osteopenia osteoporosis must receive appropriate treatment osteoporosis osteopenia entry study . Patients must adequate hematologic hepatic function define following time randomization . : Neutrophils &gt; 1500/mm3 platelet &gt; 100,000/mm3 Bilirubin &lt; 1.25 X upper limit normal SGPT ( ALT ) SGOT ( AST ) &lt; 2.5 X upper limit normal Known allergy letrozole Inability comply pulmonary function test follow visit . Treatment investigational agent within 30 day Hormonal therapy ( e.g . estrogen , progestin , LHRH agonists antagonist , estrogen receptor blocker , estrogen receptor regulator , aromatase inhibitor ) within 30 day month registration Medical psychiatric condition would interfere ability provide inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>